patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_378864 | REC_0018001 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 11.2 | 66 | female | 1 | 8 | 5.2 | 3 | sotorasib 960 mg daily | 7.1 | false | MSS | 2026-03-15T05:36:02.883293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760848 | REC_0018002 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.4 | 83 | female | 1 | 28 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.2 | true | MSS | 2026-03-15T05:36:02.884040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899283 | REC_0018003 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 5.7 | 61 | female | 1 | 17 | 5.2 | 1 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:02.884843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248484 | REC_0018004 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 11.2 | 71 | female | 2 | 13 | 5.2 | 4 | entrectinib 600 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:36:02.885605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549960 | REC_0018005 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.5 | 63 | male | 1 | 13 | 4.7 | 0 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:36:02.886327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765668 | REC_0018006 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.3 | 68 | female | 1 | 12 | 5.7 | 7 | alectinib 600 mg BID | 10.7 | false | MSS | 2026-03-15T05:36:02.887333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696035 | REC_0018007 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 15.9 | 73 | female | 1 | 10 | 3.9 | 1 | osimertinib 80 mg daily | 16.4 | true | MSI-H | 2026-03-15T05:36:02.888233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971278 | REC_0018008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10 | 66 | female | 1 | 15 | 7.3 | 8 | alectinib 600 mg BID | 13.4 | true | MSI-H | 2026-03-15T05:36:02.889046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235376 | REC_0018009 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10 | 60 | female | 1 | 12 | 6.7 | 2 | entrectinib 600 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:02.889827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964887 | REC_0018010 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 11.1 | 74 | female | 2 | 13 | 4.8 | 1 | entrectinib 600 mg daily | 23.8 | true | MSS | 2026-03-15T05:36:02.890523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578412 | REC_0018011 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.6 | 55 | male | 0 | 12 | 6.6 | 6 | osimertinib 80 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:36:02.891198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244283 | REC_0018012 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.9 | 66 | female | 0 | 37 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:36:02.891867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860784 | REC_0018013 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 12 | 43 | female | 0 | 15 | 5.1 | 5 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:02.892741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830377 | REC_0018014 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 6.5 | 69 | female | 1 | 15 | 6.8 | 6 | pembrolizumab 200 mg q3w | 7.3 | false | MSS | 2026-03-15T05:36:02.893492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626005 | REC_0018015 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9.3 | 59 | female | 0 | 20 | 5.8 | 8 | alectinib 600 mg BID | 16.1 | true | MSS | 2026-03-15T05:36:02.894258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772051 | REC_0018016 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 9.8 | 53 | female | 0 | 9 | 6.8 | 0 | osimertinib 80 mg daily | 54.1 | false | MSS | 2026-03-15T05:36:02.895003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363420 | REC_0018017 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.5 | 64 | male | 0 | 51 | 4.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.6 | true | MSS | 2026-03-15T05:36:02.895751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848091 | REC_0018018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.8 | 63 | male | 0 | 20 | 5 | 5 | alectinib 600 mg BID | 15.4 | true | MSI-H | 2026-03-15T05:36:02.896580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.